290 related articles for article (PubMed ID: 18835010)
1. Brave new world: the current and future use of novel anticoagulants.
Spyropoulos AC
Thromb Res; 2008; 123 Suppl 1():S29-35. PubMed ID: 18835010
[TBL] [Abstract][Full Text] [Related]
2. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Harenberg J; Wehling M
Semin Thromb Hemost; 2008 Feb; 34(1):39-57. PubMed ID: 18393142
[TBL] [Abstract][Full Text] [Related]
3. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
4. Novel anticoagulant therapy: principle and practice.
Mousa SA
Methods Mol Biol; 2010; 663():157-79. PubMed ID: 20617417
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Quinlan DJ; Eriksson BI
Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Contractor T; Levin V; Martinez MW; Marchlinski FE
Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
[TBL] [Abstract][Full Text] [Related]
9. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
[TBL] [Abstract][Full Text] [Related]
10. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
11. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Sattari M; Lowenthal DT
Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
[TBL] [Abstract][Full Text] [Related]
12. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
13. [New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Blanco-Molina A
Rev Clin Esp; 2012 Jan; 212 Suppl 1():3-7. PubMed ID: 23117646
[TBL] [Abstract][Full Text] [Related]
14. New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Morris TA
Clin Chest Med; 2010 Dec; 31(4):707-18. PubMed ID: 21047577
[TBL] [Abstract][Full Text] [Related]
15. Novel oral anticoagulants: a review of new agents.
Wanat MA
Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
[TBL] [Abstract][Full Text] [Related]
16. New oral anticoagulants in elderly patients.
Barco S; Cheung YW; Eikelboom JW; Coppens M
Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Khemasuwan D; Suramaethakul N
Clin Appl Thromb Hemost; 2012 Sep; 18(5):476-86. PubMed ID: 22387584
[TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Steffel J; Braunwald E
Eur Heart J; 2011 Aug; 32(16):1968-76, 1976a. PubMed ID: 21421599
[TBL] [Abstract][Full Text] [Related]
19. Factor Xa and thrombin as targets for new oral anticoagulants.
Weitz JI
Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
[TBL] [Abstract][Full Text] [Related]
20. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Eriksson BI; Quinlan DJ; Eikelboom JW
Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
